+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Oncology Drugs Market Research Reports

Pegfilgrastim- Biosimilar Insight, 2022 - Product Thumbnail Image

Pegfilgrastim- Biosimilar Insight, 2022

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Head & Neck Carcinoma - Epidemiology Forecast - 2032 - Product Thumbnail Image

Head & Neck Carcinoma - Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Multiple Myeloma - Epidemiology Forecast to 2032 - Product Thumbnail Image

Multiple Myeloma - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Follicular Lymphoma - Epidemiology Forecast to 2032 - Product Thumbnail Image

Follicular Lymphoma - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Osteosarcoma - Epidemiology Forecast to 2032 - Product Thumbnail Image

Osteosarcoma - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
From
From
Endometrial Cancer - Epidemiology Forecast to 2032 - Product Thumbnail Image

Endometrial Cancer - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Ewing Sarcoma - Epidemiology Forecast to 2032 - Product Thumbnail Image

Ewing Sarcoma - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Gastric Cancer - Epidemiology Forecast to 2032 - Product Thumbnail Image

Gastric Cancer - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
Renal cell carcinoma - Epidemiology Forecast to 2032 - Product Thumbnail Image

Renal cell carcinoma - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Anaplastic Astrocytoma - Epidemiology Forecast to 2032 - Product Thumbnail Image

Anaplastic Astrocytoma - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Chemotherapy Induced Anemia - Epidemiology Forecast to 2032 - Product Thumbnail Image

Chemotherapy Induced Anemia - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Medulloblastoma - Epidemiology Forecast to 2032 - Product Thumbnail Image

Medulloblastoma - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Myelodysplastic Syndrome - Epidemiology Forecast to 2032 - Product Thumbnail Image

Myelodysplastic Syndrome - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Gorlin Syndrome - Epidemiology Forecast to 2032 - Product Thumbnail Image

Gorlin Syndrome - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Desmoid Tumors - Epidemiology Forecast - 2032 - Product Thumbnail Image

Desmoid Tumors - Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Actinic Keratosis - Epidemiology Forecast - 2032 - Product Thumbnail Image

Actinic Keratosis - Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Loading Indicator

The Oncology Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat cancer. These drugs are used to treat a variety of cancers, including breast, lung, and prostate cancer. Oncology drugs are typically administered intravenously or orally, and can be used in combination with other treatments such as radiation and chemotherapy. The Oncology Drugs market is highly competitive, with many large pharmaceutical companies vying for market share. Some of the major players in the market include Bristol-Myers Squibb, Merck & Co., Pfizer, Novartis, and Roche. These companies are constantly researching and developing new drugs to treat cancer, as well as improving existing treatments. Additionally, many smaller companies are also involved in the Oncology Drugs market, providing innovative treatments and therapies. Show Less Read more